These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34076794)

  • 41. Specific absorbed fractions for a revised series of the UF/NCI pediatric reference phantoms: internal electron sources.
    Schwarz BC; Godwin WJ; Wayson MB; Dewji SA; Jokisch DW; Lee C; Bolch WE
    Phys Med Biol; 2021 Jan; 66(3):035005. PubMed ID: 33142278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiation Dose and Hazard Assessment of Potential Contamination Events During Use of 223Ra Dichloride in Radionuclide Therapy.
    Stabin MG; Siegel JA
    Health Phys; 2015 Sep; 109(3):212-7. PubMed ID: 26222216
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up.
    Pacilio M; Ventroni G; Cassano B; Ialongo P; Lorenzon L; Di Castro E; Recine F; Sternberg CN; Mango L
    Ann Nucl Med; 2016 Feb; 30(2):163-8. PubMed ID: 26613714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reliability of a new biokinetic model of zirconium in internal dosimetry: part I, parameter uncertainty analysis.
    Li WB; Greiter M; Oeh U; Hoeschen C
    Health Phys; 2011 Dec; 101(6):660-76. PubMed ID: 22048485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of dosimetry and biological effects in metastatic castration-resistant prostate cancer (mCRPC) patients treated with
    Sciuto R; Rea S; Ungania S; Testa A; Dini V; Tabocchini MA; Patrono C; Soriani A; Palma V; Marconi R; Strigari L
    J Exp Clin Cancer Res; 2021 Sep; 40(1):281. PubMed ID: 34488829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
    McGann S; Horton ER
    Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Review of Palliative
    Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T
    J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection and quantification of
    Mínguez P; Gómez de Iturriaga A; Fernández IL; Rodeño E
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):20-27. PubMed ID: 28645684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Organ dose calculator for diagnostic nuclear medicine patients based on the ICRP reference voxel phantoms and biokinetic models.
    Villoing D; Kwon TE; Pasqual E; Kitahara CM; Lee C
    Biomed Phys Eng Express; 2022 Dec; 9(1):. PubMed ID: 36541462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ICRP Publication 134: Occupational Intakes of Radionuclides: Part 2.
    Paquet F; Bailey MR; Leggett RW; Lipsztein J; Fell TP; Smith T; Nosske D; Eckerman KF; Berkovski V; Ansoborlo E; Giussani A; Bolch WE; Harrison JD;
    Ann ICRP; 2016 Dec; 45(3-4):7-349. PubMed ID: 28657340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radiation dosimetry of [
    Sandgren K; Johansson L; Axelsson J; Jonsson J; Ögren M; Ögren M; Andersson M; Strandberg S; Nyholm T; Riklund K; Widmark A
    EJNMMI Phys; 2019 Jan; 6(1):2. PubMed ID: 30631980
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ICRP Task Group 95: internal dose coefficients.
    Paquet F; Harrison J
    Ann ICRP; 2018 Oct; 47(3-4):63-74. PubMed ID: 29658294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis.
    Vigna L; Matheoud R; Ridone S; Arginelli D; Della Monica P; Rudoni M; Inglese E; Brambilla M
    Phys Med; 2011 Jul; 27(3):144-52. PubMed ID: 20864370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Basis for the ICRP's updated biokinetic model for systemic astatine.
    Leggett R; Samuels C
    J Radiol Prot; 2022 Feb; 42(2):. PubMed ID: 34991086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reliability of the ICRP's dose coefficients for members of the public. III. Plutonium as a case study of uncertainties in the systemic biokinetics of radionuclides.
    Leggett RW
    Radiat Prot Dosimetry; 2003; 106(2):103-20. PubMed ID: 14653331
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer.
    Pratt BE; Hindorf C; Chittenden SJ; Parker CC; Flux GD
    Nucl Med Commun; 2018 Feb; 39(2):125-130. PubMed ID: 29189490
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
    Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases.
    Yoshida K; Kaneta T; Takano S; Sugiura M; Kawano T; Hino A; Yamamoto T; Shizukuishi K; Kaneko M; Zurth C; Inoue T
    Ann Nucl Med; 2016 Aug; 30(7):453-60. PubMed ID: 27272279
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
    Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.